Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2012-11-23 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec Receives CIR (French Research Tax Credit) Accreditation
Earnings Release Classification · 99% confidence The document is a short press release dated November 23, 2012, announcing that Evotec AG received CIR (French Research Tax Credit) accreditation. It details the implications of this accreditation for their French customers. It is not a formal financial report (like 10-K or IR), an earnings release (ER), a management discussion (MDA), or a proxy statement. It is a specific corporate announcement regarding a regulatory/tax status update. Since it doesn't fit neatly into the specific categories like DIRS, DIV, or CAP, and it is a general corporate news item distributed via DGAP, the most appropriate fallback category is Regulatory Filings (RNS), as it is a miscellaneous regulatory/operational update that doesn't match the other specific types. FY 2012
2012-11-23 English
Earnings Release 2012
Earnings Release Classification · 99% confidence The document is a research publication from DZ BANK AG concerning the company Evotec. It contains detailed financial forecasts (2011 actuals, 2012e-2014e estimates), analysis of a recent quarterly performance ('Ein schwächeres Quartal macht noch keinen Winter'), investment ratings ('Kaufen'), and extensive financial tables covering P&L, balance sheet, and valuation metrics. This structure is characteristic of an equity research report providing analysis and forward-looking estimates, rather than an official regulatory filing like a 10-K, an earnings release (ER), or a simple announcement (RPA/RNS). Since it is a detailed research publication with forecasts and investment recommendations, the most appropriate category is 'Investor Presentation' (IP) or a general research/analysis category. Given the options, 'Investor Presentation' (IP) often encompasses detailed research reports used for investor communication, although 'MDA' (Management Reports) or 'AR' (Audit Report/Information) are less fitting. However, this is clearly a third-party research document, not a company filing. Since there is no specific 'Equity Research Report' code, and the content is highly analytical and forward-looking, it most closely aligns with the depth and purpose of an Investor Presentation (IP) or a general analysis document. Given the context of financial document classification, this type of detailed, proprietary analysis report is often grouped with investor materials. I will classify it as 'Investor Presentation' (IP) as it serves a similar function of presenting deep analysis to investors, though it is technically a research note. FY 2012
2012-11-19 German
Evotec partners with Haplogen to develop drugs for infectious diseases
Regulatory Filings Classification · 100% confidence The document is a short press release dated November 15, 2012, announcing a collaboration agreement between Evotec AG and Haplogen GmbH regarding drug development. It contains standard elements of a corporate news announcement, including a headline, key details of the partnership, quotes from management, and boilerplate forward-looking statements. It is explicitly distributed via 'DGAP - a company of EquityStory AG' as a 'Corporate News'. Since this is a specific announcement of a business event (an alliance/partnership) and not a formal regulatory filing like a 10-K, an earnings release (ER), or a report itself, it fits best under the general category for miscellaneous regulatory announcements or corporate news that doesn't fit a more specific category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news release distributed via a service like DGAP, especially since there is no specific category for 'Partnership Announcement'. However, since it is a specific corporate event announcement, and not a mandatory regulatory filing like a major shareholding change or director's dealing, RNS serves as the best fit among the provided codes for general corporate news.
2012-11-15 English
Evotec reports 8% revenue growth and a positive operating result of EUR2.9 m in the first nine months of 2012
Earnings Release Classification · 100% confidence The document text explicitly states it reports 'financial results and corporate updates for the third quarter and first nine months of 2012 ending 30 September 2012.' It details revenues, operating results, liquidity, and significant operational milestones achieved during that period. This content structure—a comprehensive review of financial performance and business activities for a period shorter than a full year (nine months)—is characteristic of an Interim/Quarterly Report. The presence of specific financial figures and operational updates, rather than just an announcement of a report's release, rules out RPA (Report Publication Announcement). Therefore, the classification is Interim / Quarterly Report (IR). 9M 2012
2012-11-08 English
Earnings Release 2012
Earnings Release Classification · 99% confidence The document contains detailed financial analysis, including revenue figures for '9M/2012' (Nine Months 2012), EBIT, EPS estimates, forward-looking projections (2012E, 2013E, 2014E), valuation methods, and a recommendation system (BUY/HOLD/SELL). It explicitly mentions being a 'financial analysis' and includes extensive disclaimers according to German Securities Trading Act (§ 34b WpHG). This structure is characteristic of an equity research report or an investment analysis, which aligns best with the 'Investor Presentation' (IP) or potentially a specialized 'Interim/Quarterly Report' (IR) if it were the company's own filing. However, given the context of an external analyst providing a BUY recommendation, price target, and detailed valuation tables, it functions as an Investment Research Report. Among the provided codes, 'IP' (Investor Presentation) is the closest fit for detailed, forward-looking analysis provided by a third party, although 'MDA' (Management Reports) or 'IR' (Interim Report) might cover the underlying data. Since this is clearly an external research document summarizing interim results and providing forecasts, 'IP' (Investor Presentation) is the most appropriate classification for this type of analytical output, as it presents investment rationale and data summaries. Revisiting the definitions: It is not a 10-K (Annual Report), not an ER (Earnings Release - which is just the initial announcement), and not an IR (Interim Report - which is the official company filing). It is an analyst's report. 'IP' (Investor Presentation) is often used for detailed analyst reports that summarize performance and strategy for investors. FY 2012
2012-11-08 English
Evotec AG , Q3 Results 2012
Investor Presentation Classification · 98% confidence The document text contains slides from a presentation, indicated by the structure ('# Action Pla Gaining M an 2016 –Momentum', '## Highlights Q3 2012', '## EVT Execute:', '## EVT Innovate:', and tables detailing clinical assets). It discusses financial performance ('Group revenues +8% to €64.2 m'), strategic plans ('Action Plan 2016'), and pipeline progress (Phase III trial for DiaPep277, Phase II trial for EVT 302). This content strongly aligns with an Investor Presentation (IP), which typically includes strategic updates, financial highlights for a period (Q3 2012 mentioned), and pipeline information, often presented in a slide deck format. It is not a formal regulatory filing like a 10-K or an Earnings Release (ER) which is usually a press release summary, nor is it a transcript (CT). Given the detailed, visual, and strategic nature, Investor Presentation (IP) is the most appropriate classification.
2012-11-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.